Investigational · not FDA approved

Editorially reviewed · Last updated May 2026 · How we review

Switching to Retatrutide from Tirzepatide or Semaglutide

Retatrutide is not yet approved by the FDA and is not available by prescription. As of February 2026, there is no way to switch from semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) to retatrutide outside of a clinical trial. No switching protocols exist because the drug has not reached the market.

This article covers what we know about switching between GLP-1 class drugs generally, why people are interested in retatrutide specifically, and how to find clinical trials if you want to explore access before approval.

Why People Want to Switch

Interest in switching to retatrutide is driven by its clinical trial results, which show substantially larger weight loss than currently approved drugs:

Drug	Mechanism	Max Weight Loss (Trials)	Status
Semaglutide (Wegovy)	GLP-1 (1 receptor)	~15-17%	Approved
Tirzepatide (Zepbound)	GLP-1 + GIP (2 receptors)	~21-23%	Approved
Retatrutide	GLP-1 + GIP + Glucagon (3 receptors)	~28.7%	Phase 3 trials

Retatrutide's triple-agonist mechanism adds glucagon receptor activation to the GLP-1 and GIP agonism found in tirzepatide. The glucagon component increases energy expenditure and promotes fat breakdown, which may explain the larger weight loss observed in trials. For people who have plateaued on semaglutide or tirzepatide, the possibility of a more effective drug is understandably appealing.

For a full explanation of the three receptors, see What Is Retatrutide (GLP-3)?.

Current Status: Not Available Outside Clinical Trials

To be direct: you cannot switch to retatrutide right now. Here is the current timeline:

Phase 3 TRIUMPH trials are underway, with results expected throughout 2026
NDA filing (the formal FDA application) is expected in late 2026 or early 2027
FDA approval, if granted, is most likely in 2027
Prescription availability would follow shortly after approval

Anyone claiming to sell retatrutide outside a clinical trial is selling an unregulated, unverified product. For more on this, see Retatrutide Cost & How to Get It.

For the full regulatory timeline, see Retatrutide FDA Approval Timeline.

What We Know About Switching Between GLP-1 Drugs

While no retatrutide-specific switching data exists, there is established clinical experience with switching between existing GLP-1 receptor agonists. Here is what that experience tells us:

No washout period is typically needed

When switching between semaglutide and tirzepatide (or between other GLP-1 drugs), clinicians generally do not require a washout period — a gap between stopping one drug and starting another. The standard practice is to stop the current medication and start the new one at the next scheduled dosing time.

Dose titration usually restarts

When switching to a new GLP-1 drug, patients typically begin at the starting dose and titrate up, regardless of what dose they were on previously. This is because different drugs have different potencies, receptor profiles, and side effect patterns. Starting at a high dose of a new drug based on the previous drug's dose could cause unnecessary side effects.

GI side effects may recur

Even if a patient has adapted to GI side effects on their current medication, switching to a new drug — especially one with a different receptor profile — may trigger a new round of nausea, diarrhea, or other GI symptoms during the titration phase.

Each drug has a different receptor profile

This is particularly relevant for a hypothetical switch to retatrutide:

Drug	GLP-1	GIP	Glucagon
Semaglutide	Yes	No	No
Tirzepatide	Yes	Yes	No
Retatrutide	Yes	Yes	Yes

A patient switching from semaglutide to retatrutide would be adding two entirely new receptor activations (GIP and glucagon). A patient switching from tirzepatide would be adding one (glucagon). The glucagon component in particular could introduce new physiological effects — both therapeutic (increased energy expenditure, liver fat reduction) and in terms of side effects.

How to Access Retatrutide Through Clinical Trials

The only legitimate way to receive retatrutide today is through Eli Lilly's Phase 3 clinical trial program. Several trials may still be recruiting participants.

How to search for trials

ClinicalTrials.gov — Search for "retatrutide" on ClinicalTrials.gov to see all registered trials, their locations, and eligibility criteria.
Lilly Trial Finder — Visit LillyTrialGuide.com for Eli Lilly's own trial search tool.
Ask your doctor — Your physician can help determine if you meet eligibility criteria and refer you to a participating trial site.

What to expect

Clinical trial participants receive the study drug at no cost
You may be randomized to placebo — there is no guarantee you will receive retatrutide
Participants are monitored with regular medical visits, blood work, and assessments
Most trials require you to stop any current GLP-1 medication before enrolling (with a defined washout period specified in the trial protocol)

What Happens After Approval

Once retatrutide is approved — potentially in 2027 — switching protocols will be developed based on real-world clinical data and prescriber experience. At that point, the decision to switch will involve:

Evaluating your response to current therapy — if you are achieving good results on semaglutide or tirzepatide, switching may not be necessary
Discussing potential benefits — retatrutide's triple mechanism may offer advantages for specific patients, particularly those with plateau weight loss, fatty liver disease, or inadequate response to current drugs
Insurance and cost considerations — a new brand-name drug will likely have different coverage than established medications, especially if generic or biosimilar versions of semaglutide become available
Titration planning — you and your doctor will need to plan the transition, including when to stop the current drug and how to titrate the new one

Switching is one direction of a larger decision. If you are weighing whether to come off a GLP-class drug entirely rather than move to another one, see stopping retatrutide: what happens when you come off for the weight-regain evidence and the stop-versus-maintain options.

Frequently Asked Questions

Can I switch from Ozempic or Wegovy to retatrutide?

Not currently. Retatrutide is an investigational drug in Phase 3 clinical trials and is not available by prescription. No switching protocols exist because the drug has not been approved. The earliest retatrutide could become available is 2027, pending FDA approval.

Will I need to stop my current GLP-1 medication before starting retatrutide?

When retatrutide becomes available, this will be a clinical decision made with your doctor. Based on existing practice with GLP-1 drugs, you would likely stop your current medication and start retatrutide at the beginning dose with a standard titration schedule. No washout period is typically required when switching between GLP-1 class drugs.

Will retatrutide work better than my current medication?

Retatrutide's Phase 3 trial results show greater weight loss than has been achieved with semaglutide or tirzepatide in their respective trials (28.7% vs. ~15-17% and ~21-23%). However, individual responses vary widely, and cross-trial comparisons are not the same as head-to-head data. No published trial has directly compared retatrutide against tirzepatide or semaglutide in the same study. For a detailed comparison, see Retatrutide vs Mounjaro vs Ozempic.

Is gray market retatrutide a way to switch early?

No. Gray market peptides are unregulated, unverified, and potentially dangerous. They are not manufactured under pharmaceutical-grade conditions and may contain incorrect doses, contaminants, or entirely different substances. There is no legitimate way to obtain retatrutide outside of a clinical trial. See Retatrutide Cost & How to Get It for more detail.

What should I do while waiting for retatrutide?

Talk to your doctor about optimizing your current treatment. If you are on semaglutide and have plateaued, switching to tirzepatide may offer additional weight loss — this is a switch that is possible today with FDA-approved drugs. You can also ask your doctor about clinical trial eligibility if you are interested in accessing retatrutide before approval.

Can I take retatrutide and another GLP-1 drug at the same time?

No clinical trial has tested combining retatrutide with semaglutide, tirzepatide, or any other GLP-1 receptor agonist. The TRIUMPH Phase 3 trials explicitly exclude participants who have taken any weight loss medication within 90 days of screening, and the trial protocol classifies concurrent obesity management medications as prohibited treatments.

There is also no pharmacological rationale for stacking. Retatrutide already activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Adding semaglutide (which targets GLP-1 alone) or tirzepatide (which targets GLP-1 and GIP) would duplicate receptor activation that retatrutide already provides — without adding a new mechanism — while compounding the side-effect burden, particularly gastrointestinal effects like nausea, vomiting, and diarrhea.

If you are not seeing adequate results on your current GLP-1 medication, the evidence-supported options are optimizing your current dose, switching to a more potent single agent (e.g., from semaglutide to tirzepatide), or discussing clinical trial enrollment for retatrutide with your physician — not adding a second drug on top.

Sources

Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
Giblin, M.J., et al. (2026). Design of the TRIUMPH Phase 3 program for retatrutide in obesity. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70209
ClinicalTrials.gov: Retatrutide trials, TRIUMPH-4 (NCT05929066)

Questions to ask your doctor

Given my health history, is a GLP-1 medication appropriate for me at all?
Which approved option (e.g. semaglutide, tirzepatide) best fits my goals?
What starting dose and titration pace would you use, and why?
What side effects should I watch for, and when should I call you?
How will we monitor whether it's working and when to adjust?

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources